Subscribe to Newsletter

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a Deputy Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Content by Roisin McGuigan:

Manufacture Clinical Trials

A Tall Task

| Roisin McGuigan

The PRGLAC Task Force hopes to change the landscape for research on pregnant and lactating women.

Manufacture Clinical Trials

Time for Pharma to Deliver?

| Roisin McGuigan

Is pharma putting women and children last?

Discovery & Development Drug Delivery

Injectable Innovation

| Roisin McGuigan

A company looks to give the humble injection an inventive makeover.

Business & Regulation Standards & Regulation

The True Cost of Falsified Medicine

| Roisin McGuigan

A recent review and meta-analysis highlights the huge impact of fake and substandard drugs.

Manufacture Technology and Equipment

Bearfaced Research

| Roisin McGuigan

A new method for discovering antibiotics makes use of an unusual source of complex microbial communities: bear saliva.

Discovery & Development Drug Delivery

Eliminating Side Effects In Silico

| Roisin McGuigan

Next-generation pain medications could improve on current opioid offerings.

Manufacture Clinical Trials

A (Pregnant) Pause For Thought

| Roisin McGuigan

It’s time for maternal health to move on from the dark ages, and pharma has a duty to help.

Business & Regulation Business Practice

Let’s Talk About Mental Health

| Roisin McGuigan

A recent survey examined the relationships – or lack thereof – between pharma companies and mental health patient groups

Discovery & Development Clinical Trials

Bringing Alzheimer’s in from the Cold

| Roisin McGuigan

With big pharma seemingly pulling out of the field, what hope remains for novel treatments for Alzheimer’s disease?

Business & Regulation Standards & Regulation

Too Many Cooks

| Roisin McGuigan

Thought that most companies understood good manufacturing practice? Think again – there are always a few bad eggs.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register